| Autor: |
Sanders-Beer, Brigitte E., Archin, Nancie M., Brumme, Zabrina L., Busch, Michael P., Deleage, Claire, O'Doherty, Una, Hughes, Stephen H., Jerome, Keith R., Jones, R. Brad, Karn, Jonathan, Kearney, Mary F., Keele, Brandon F., Kulpa, Deanna A., Laird, Gregory M., Li, Jonathan Z., Lichterfeld, Mathias D., Nussenzweig, Michel C., Persaud, Deborah, Yukl, Steven A., Siliciano, Robert F. |
| Zdroj: |
AIDS Research & Human Retroviruses; Jan2024, Vol. 40 Issue 1, p7-21, 15p |
| Abstrakt: |
Since the first HIV-cured person was reported in 2009, a strong interest in developing highly sensitive HIV and SIV reservoir assays has emerged. In particular, the question arose about the comparative value of state-of-the-art assays to measure and characterize the HIV reservoir, and how these assays can be applied to accurately detect changes in the reservoir during efforts to develop a cure for HIV infection. Second, it is important to consider the impact on the outcome of clinical trials if these relatively new HIV reservoir assays are incorporated into clinical trial endpoints and/or used for clinical decision-making. To understand the advantages and limitations and the regulatory implications of HIV reservoir assays, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored and convened a meeting on September 16, 2022, to discuss the state of knowledge concerning these questions and best practices for selecting HIV reservoir assays for a particular research question or clinical trial protocol. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
